Abstract Purpose: There is an urgent need to develop diagnostic tests to improve the detection of pathogens causing life-threatening infection (sepsis). SeptiFast is a CEmarked multi-pathogen real-time PCR system capable of detecting DNA sequences of bacteria and fungi present in blood samples within a few hours. We report here a systematic review and meta-analysis of diagnostic accuracy studies of SeptiFast in the setting of suspected sepsis. Methods: A comprehensive search strategy was developed to identify studies that compared SeptiFast with blood culture in suspected sepsis. Methodological quality was assessed using QUADAS. Heterogeneity of studies was investigated using a coupled forest plot of sensitivity and specificity and a scatter plot in receiver operator characteristic space. Bivariate model method was used to estimate summary sensitivity and specificity. Results: From 41 phase III diagnostic accuracy studies, summary sensitivity and specificity for SeptiFast compared with blood culture were 0.68 (95 % CI 0.63-0.73) and 0.86 (95 % CI 0.84-0.89) respectively. Study quality was judged to be variable with important deficiencies overall in design and reporting that could impact on derived diagnostic accuracy metrics.
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Conclusions: SeptiFast appears to have higher specificity than sensitivity, but deficiencies in study quality are likely to render this body of work unreliable. Based on the evidence presented here, it remains difficult to make firm recommendations about the likely clinical utility of SeptiFast in the setting of suspected sepsis.
Introduction
While rapid identification and treatment of sepsis are associated with the best outcomes, sepsis can be difficult to diagnose and to differentiate from other common noninfectious causes of systemic inflammation including trauma, surgery and ischaemia-reperfusion [1] . Confirmation of sepsis, therefore, relies on objective diagnostic evidence for infection, including attempts to detect and identify live pathogens from blood samples by microbiological culture techniques [2, 3] .
In the setting of sepsis, blood cultures do not always provide high diagnostic accuracy for infection in a timely manner, routinely taking several days before a positive result is available and are often negative [4] . The time between initial clinical suspicion and confirmation of infection leads to the early use of empirical broad-spectrum antimicrobial drugs because treatment delay is associated with substantial increases in mortality [5] [6] [7] . Unnecessary and/or prolonged broad-spectrum antimicrobial use is an inevitable consequence, which is associated with the development of drug-resistant pathogens, Clostridium difficile infections, a range of avoidable adverse effects, as well as high costs [5] . An urgent global challenge has emerged [8] , therefore, to develop techniques that could provide accurate diagnostic information within a short timeframe of clinical signs appearing and so allow more informed use of antibiotic therapy at an early stage.
Real-time PCR technology can detect minute amounts of pathogen DNA in patient blood samples with results available within hours [9] . Laboratory validation studies have focused on two approaches using PCR for genomic amplification with either (a) broad-range detection of bacterial or fungal DNA with universal primers, followed by species identification using a post-PCR technique such as gene sequencing or electrospray mass spectrometry or (b) using species-specific hybridisation probes that provide direct confirmation of the species present [10] . While the laboratory analytical accuracy of these techniques for the detection of pathogen DNA in blood has been evaluated, there is a lack of reported clinical trial data to define the utility of such tests in patients [2, 10] . This has been due in part to the lack of standardised technology platforms that meet accepted regulatory standards for clinical diagnosis.
SeptiFast, manufactured by Roche Diagnostics, GmbH, Mannheim, Germany and run on their real-time PCR instrument (the LightCycler Ò ), was the first realtime PCR-based system to be awarded a Conformité Européenne (CE) mark for simultaneous pathogen detection and identification in suspected bloodstream infection [11] . The system uses a multiplex approach, which allows detection of the most common pathogen species causing bloodstream infection in a single blood sample ( Table 1) . Identification of the pathogens is based on the use of species-specific probes targeting the internal transcribed spacer region between the 16S and 23S areas of ribosomal DNA of bacteria and between the 18S and 5.8S ribosomal regions of the fungal genome. SeptiFast has been assessed at the laboratory level on clinical isolates and shown to have good analytical specificity and exclusivity, confirming its analytical validity [11] . Numerous clinical diagnostic studies have been reported since SeptiFast gained its CE mark in 2006, predominantly focused on suspected sepsis. Chang and colleagues have reported a diagnostic accuracy systematic review of published full journal papers to 2012, with SeptiFast as the index test, but with various reference standards used to produce composite overall diagnostic accuracy metrics [12] . On the basis of their interpretation of the evidence presented, they recommend that SeptiFast can be used to confidently diagnose bloodstream infection [12] .
As part of a government-commissioned Health Technology Assessment of SeptiFast in the UK [13] , we report a more comprehensive diagnostic accuracy systematic review of SeptiFast focused on the setting of suspected sepsis and where blood cultures were used as the reference standard. This systematic review was piloted and registered with PROSPERO, the National Institute of Health Research (NIHR) International Prospective Register of Systematic Reviews, in 2011 [14] and the study protocol was piloted and published in 2012 [15] . 
Methods

Inclusion criteria of studies
Participants
Patients suspected of developing sepsis, including adults and children, who required blood cultures irrespective of where their care was being delivered, and including suspected community or hospital acquired infection.
Target conditions
Suspected sepsis, including severe sepsis and septic shock [16] .
Index test
LightCycler Ò SeptiFast as the index test on blood specimens for the detection and simultaneous identification of bacterial and fungal pathogens [11] .
Comparator test (reference standard)
Blood culture for the detection and identification of bloodstream bacterial and fungal pathogens was used as the reference test [4] .
Types of studies
We included any clinical diagnostic accuracy study that compared the index real-time PCR test with standard culture results performed on a patient's blood sample during the management of suspected sepsis.
Search methods for identifying studies
Electronic searches
We searched the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE), the Health Technology Assessment Database (HTA), the NHS Economic Evaluation Database (NHSEED), The Cochrane Library, MEDLINE, EM-BASE, ISI Web of Science, BIOSIS Previews, MEDION and the Aggressive Research Intelligence Facility database (ARIF). The CE mark for the index test was announced in January 2006; therefore, this systematic review only considered publications from this date in humans. There were no language restrictions in the electronic search for studies.
Search terms/search strategy
Specific search strategies were developed for each electronic database, commencing with MEDLINE (published previously) [14, 15] . The MEDLINE strategy was adapted for each subsequent database. All electronic searches were piloted prior to publication of our review protocol in 2012 and all searches were finally updated at the end of April 2014.
Other resources
Backward tracking was performed by hand-searching the reference lists of all relevant articles uncovered from the electronic searches and forward tracking using the keyword 'SeptiFast' with ISI Citation Indices and Google Scholar and with a conference proceedings search using the Web of Science ISI Proceedings (from January 2006 to April 2014). We requested reference lists held by the only manufacturer of the index test (Roche Diagnostics) and requested any clinical diagnostic accuracy data collected by Roche Diagnostics to file for the CE mark. In addition, we searched for unpublished studies and ongoing trials involving the SeptiFast platform in the following online registers: http://www.nlm.nih.gov/hsrpr oj, http://www.controlled-trials.com/mrct/, http://portal.nihr. ac.uk/Pages/Portfolio.aspx and http://www.who.int/trialsear ch, with identified corresponding authors of eligible trials and content experts contacted to identify potentially relevant studies and associated data.
Data collection and analysis
Selection of studies (Salford, UK)
The selection of titles and abstracts was conducted by review authors (CW, DG, KT and PD) using the inclusion criteria detailed above. The full papers of all abstracts deemed eligible (by any reviewer) were obtained and read to determine their inclusion in the review. Conference abstracts and journal correspondences were included if they met the inclusion criteria and the corresponding author was contacted to request any further information about their study or about full publications in preparation. Conference abstracts were not included when reporting duplicate data contained in a subsequent paper. We resolved any disagreement for inclusion with discussion between the reviewers.
Assessment of methodological quality (Belfast and Warwick, UK)
Independent reviewers from Belfast (DM, RM, BB) and Warwick (GDP) assessed the quality of selected studies using a specific checklist, published previously [15] adapted from the QUADAS tool [17] . Each question on the checklist was answered with a yes/no response or noted as unclear if insufficient information was reported to enable a judgement to be made, and the reasons for the judgement made were documented. Review authors assessed methodological quality independently. Any subsequent discrepancies were then adjudicated and resolved by a systematic review methods expert (BB) and an infection diagnostic expert (RM).
Data extraction
A standard set of data was searched for and extracted where possible from each study using a tailored data extraction form (details published previously) [15] by review authors at Belfast and Warwick. Reviewers extracted data independently and any discrepancies were adjudicated and resolved by a systematic review methods expert (BB) and an infection diagnostic expert (RM).
Statistical analysis and data synthesis
Statistical analysis and data synthesis were planned and performed independently by a statistician (SG). Estimates of the combined sensitivity and specificity, with 95 % confidence intervals, were made using Reitsma's bivariate method [18] . Results were displayed as summary ROC plots, with 95 % confidence regions and 95 % prediction regions defined by Harbord as ''the region within which, assuming the model is correct, we have 95 % confidence that the true sensitivity and specificity of a future study should lie'' [19] . An overall summary for all studies with useable data was produced, and subgroup analyses separating studies by For all subgroup analyses, summary ROC curves were produced with pooled estimates of sensitivity and specificity for each group, and tested whether the subgrouping explained a significant amount of additional variation using the difference in -2log likelihood statistics between the subgrouped and overall models.
No attempts were made to quantify potential sources of study bias in this systematic review as the available methodologies have not been validated for use in relation to diagnostic test meta-analyses (http://srdta.cochrane. org/handbook-dta-reviews).
Analyses were performed using SAS 9. 
Results
Study inclusion
We identified 2,759 citations in total, of which 66 were considered potentially suitable (Fig. 1) . After full-text review externally at Belfast and Warwick, and having contacted corresponding authors for any extra data in the case of conference abstracts and journal correspondences, 24 studies were excluded as it proved impossible to derive a 2 by 2 table to calculate required diagnostic metrics. In addition, one abstract was removed as the study data were co-reported in a full paper and another abstract was replaced by a full paper that was sent to us by the authors. In total, 41 studies were included in the final analysis (30 papers, 9 conference abstracts and 2 correspondences-summarised in Table 2 ).
Study quality
Our independent external reviewers reported variable study quality and, although studies reported as full papers were associated with the best quality measures, there were important deficiencies overall in study design and reporting (Fig. 2) . Reviewers agreed that all of the studies selected aimed to compare test results from SeptiFast with blood culture and that the reported blood sampling for these tests was such that disease progression or regression bias would have been avoided. Blood culture, as the reference standard, appeared to have been applied to patients equally in a way that both partial (work-up) bias and verification bias were likely avoided. However the reference standard was not always adequately described, including blood sampling methods and the prevalence of defined contamination as a potential source of false positive culture results. Comparisons of the results of SeptiFast with blood culture at genus/species level were often difficult to adjudicate by reviewers, with no clear standards of reporting followed. The chance of misclassification when comparing the reference and index tests was therefore thought to be likely, impacting on the derived diagnostic accuracy metrics. In some studies, it was not clear how well the CE-marked protocol for SeptiFast had been followed, including how blood samples had been stored/handled prior to assay delivery. Assay failure rates were rarely reported. There was a universal lack of reported blinding of both reference standard and index tests such that reviewers believed that incorporation bias was highly likely. Overall, reviewers agreed that none of the included studies, as reported, met the Standards for Reporting Diagnostic Accuracy (STARD) criteria in full [62] , and in some cases there were significant deficiencies (Fig. 2) . Indicates haemato-oncology study cohorts
Study characteristics and patient populations
Studies included patient cohorts from a wide range of age and settings (Table 2 ) representing a total of 7,727 patients contributing 10,493 episodes of suspected sepsis. The median prevalence of blood culture positivity in this group of patients was 17 % (interquartile range 13-25 %). Lack of uniform reporting made it difficult for reviewers to classify studies, with a variety of care settings, outcomes and alternative clinical reference standards reported alongside the direct comparison of SeptiFast with blood culture results. However, our external reviewers were able to identify age classes (neonate, child and adult), setting classes (emergency department, hospital setting, and intensive/critical care), commercial sponsorship (stated involvement of Roche Diagnostics or no statement) and a group of studies that focused on haemato-oncology patients. In addition, studies were assigned a diagnostic evidence level III [20] in each case.
Estimated summary diagnostic accuracy of SeptiFast Figure 3 shows the coupled forest plots of sensitivity and specificity for each study and Fig. 4 displays the scatter plot in ROC space (plotting sensitivity against 1 -specificity for each study). Summary sensitivity and specificity for SeptiFast compared with blood culture, estimated using the bivariate model method, were 0.68 (95 % CI 0.63-0.73) and 0.86 (95 % CI 0.84-0.89) respectively, suggesting that a positive blood test at genus/species level returned by SeptiFast in the setting of a patient with suspected sepsis could have higher diagnostic value (rule-in) than a negative test result (rule-out) when compared with blood culture.
Exploration of subgroups
Subgroups were investigated and estimated pooled diagnostic accuracy metrics produced for each group. Table 3 summaries these results and shows that in each case subgrouping did not explain any significant amount of additional variation in sensitivity or specificity when compared with the overall models. There were insufficient studies reporting solely in paediatric populations to allow analysis.
Discussion
Our comprehensive systematic review was designed to help understand the estimated combined diagnostic accuracy of SeptiFast in detecting and identifying bacterial and fungal pathogens in the blood of patients with suspected sepsis. We included 41 studies reporting on a total of 10,493 SeptiFast tests when compared with blood culture. Estimated combined results for sensitivity and specificity suggested that SeptiFast has a higher specificity than sensitivity. For the healthcare team, this implies that positive blood tests returned by SeptiFast at pathogen genus/species level could have higher diagnostic utility (as a rapid rule-in test) than negative results (as a rapid rule-out test), at least when compared with blood culture. The apparent confidence in this statement is greater for specificity than sensitivity (Figs. 3, 4) because the median event rate of 17 % BC positivity for the studies means that the majority of reference tests performed were negative.
The clinical interpretation of these diagnostic accuracy results is that negative SeptiFast tests could reasonably be false negatives (expressed as a low overall diagnostic sensitivity), explained in part by pathogens detected in blood culture that were not on the PCR test panel. In the future, this could suggest that developing molecular tests that incorporate wider test panels of pathogens may be expected to provide greater diagnostic sensitivity (fewer false negative results) giving clinicians greater confidence in a rapid negative test result. In addition, despite a higher estimated overall specificity, when compared with sensitivity, the upper confidence interval did not reach 90 %. Specificity of SeptiFast, when compared with culture, will be limited by the presence of false positive results-a positive PCR in the setting of a negative blood culture. In some studies [40, 41] , a proportion of these false positive results were reported to be concordant with culture positivity from samples other than blood, suggesting that in some cases a positive SeptiFast result may reflect infection not detectable by blood culture. However, overall, there are no clear explanations for all of these false positive and false negative SeptiFast results because no systematic investigation has been undertaken linking laboratory performance with clinical diagnostic accuracy. In addition, it remains extremely difficult to speculate what implications these diagnostic accuracy results may have for direct clinical care because SeptiFast does not report antibiotic sensitivity data (other than identifying the MecA gene confirming methicillin resistance following detection of S. aureus [11] ) and there have been no systematic interventional clinical trials reported to date on the overall impact on clinical, laboratory and cost-effectiveness of supplementing or replacing blood culture with SeptiFast.
All diagnostic metrics were reported using blood culture as the reference standard because this formed the basis of both the original laboratory diagnostic validity studies for SeptiFast [11] and the subsequent body of clinical diagnostic accuracy studies reported here. However, we accept that there could be limitations to this standard, particularly in the setting of intercurrent antimicrobial therapy. While antibiotic exposure data were rarely reported in the included studies, it is likely, for example, that patients in intensive care units were likely already exposed to broad-spectrum antibiotics [33] . It is interesting to note that included studies recruiting solely from intensive care appeared to have slightly worse diagnostic metrics (both sensitivity, with higher rates of false negatives; and specificity, with higher rates of false positives) when compared with the results of blood culture (Table 3) , but not to a significant level. Antimicrobial exposure is not the only factor that will distinguish patients in intensive care from other hospitalised patients, but it does seem particularly pertinent because of the widespread use of blood culture as the reference standard in these studies. The potential impact of antimicrobials in producing positive PCR tests with blood and associated negative blood culture results (false positives in our analysis) leads one to question blood culture as a relevant reference standard and challenges clinicians to consider a positive PCR test in this setting as a true positive, providing additional diagnostic information in patients with suspected sepsis. However, explaining the potential impact of antimicrobials on increasing false negative PCR tests (i.e. where associated blood culture tests are positive) is more problematic. In practice, a wide range of factors are known to influence the diagnostic accuracy of blood cultures [4] and, in our view, it is important to develop further and adopt statistical techniques that avoid the need for comparison to a single reference standard to provide a more meaningful estimate of the clinical reliability of emerging molecular diagnostic tests [63] . However, to achieve this aim, diagnostic studies must be designed and reported to accepted international standards [62] .
During the implementation of our review, another systematic review has reported on the diagnostic accuracy performance of SeptiFast [12] . Chang and colleagues synthesised improved overall diagnostic accuracy metrics for SeptiFast when compared with our own review: sensitivity 0.75 (95 % CI 0.65-0.83) vs 0.68 (95 % CI Diagnostic accuracy studies included in our review were performed within the challenging care environments for patients with suspected sepsis. Clinical diagnostic accuracy studies, in general, are difficult to perform well and often fall short in terms of study quality. Our independent reviewers found significant deficiencies when assessing the quality of design and reporting for studies incorporating SeptiFast as the index test. For both papers and abstracts, the applications of reference and index tests were the only elements that were reported consistently, raising significant concern about the possible effects of numerous sources of bias on the derived summary estimates of SeptiFast test performance. Indeed, the 95 % prediction region in ROC space in Fig. 4 shows considerable uncertainty about the likely true sensitivity and specificity of a future study. Therefore, despite the considerable international effort in determining the likely diagnostic accuracy of SeptiFast in the setting of suspected sepsis, we are not confident in the current body of evidence because of the overall weaknesses in study design and reporting outlined in our review. On the basis of these findings, we do not agree with Chang and colleagues who state that ''in the presence of a positive SeptiFast result in a patient with suspected bacterial or fungal sepsis, a clinician can confidently diagnose bacteremia or fungaemia and begin appropriate antimicrobial therapy, while forgoing unnecessary additional diagnostic testing'' [12] . For example, in a high prevalence population, such as a patient admitted to intensive care with septic shock, broad-spectrum antibiotics should have been delivered quickly, well before the results of blood culture (or indeed SeptiFast) will be available [2] . In this setting, the pre-test probability for circulating pathogens is likely high and there is an increased chance of delivering positive SeptiFast and blood culture tests, particularly if blood is sampled before antimicrobial treatment commences. Delivering a positive SeptiFast test ahead of a blood culture result in this setting might help the intensive care clinician consider early antibiotic de-escalation based on the detected pathogen species. However, SeptiFast does not provide comprehensive antimicrobial susceptibility information and crucial clinical decisions based only on pathogen species may be unwise in this setting and, as described previously, remains untested in carefully controlled clinical trials. Furthermore, we do not agree with Chang and colleagues that returning a negative SeptiFast result, even in a low prevalence population, ''may justify withholding antibiotics'' [12] . For example, a patient admitted to an emergency department with clinical features of sepsis, in the absence of circulatory compromise or organ dysfunction, is likely to have a low pre-test probability for circulating pathogen. Delivering a negative SeptiFast test to the clinical team over the subsequent hours may provide some confidence in excluding serious infection as the cause of symptoms. However, given the high rate of false negative SeptiFast tests identified in our review, the clinician is not completely confident and could miss some cases of bacteraemia and other infections outside the circulation. On the basis of the evidence presented here, we are concerned that clinical decisions about treatment interventions/adjustments (notably antimicrobial chemotherapy) based on SeptiFast results, potentially delivered within hours of the suspicion of sepsis, could expose patients to risk because inadequately managed sepsis is associated with high mortality and rapid appropriate antimicrobial choices are crucial for survival [2] .
Our views, evidenced by the present systematic review, support current international guidelines on diagnosis and treatment of sepsis which indicate that there is limited clinical experience with non-culture-based diagnostic methods, such as SeptiFast, and that more highquality clinical studies are needed before any firm recommendations can be made about their potential utility [2] . We recommend that future clinical studies incorporating SeptiFast, or any other novel infection/sepsis diagnostic, should include well-designed and reported clinical diagnostic accuracy elements measured against all of the features of the STARD criteria [62] . Much needed clinical intervention studies in the setting of suspected sepsis remain difficult to design and justify until higher-quality clinical diagnostic accuracy evidence is available.
